U.S. Point-of-Care Glucose Testing Market Size, Share & Trends Analysis Report By Product (Accu-Chek Inform II, Freestyle Lite, True Metrix, i-STAT, StatStrip, Onetouch Verio Flex, Bayer CONTOUR Blood Glucose Monitoring System), And Segment) - Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2024-2033

The U.S. point-of-care glucose testing market size was estimated at USD 1.21 billion in 2023 and is projected to hit around USD 1.90 billion by 2033, growing at a CAGR of 4.6% during the forecast period from 2024 to 2033.

U.S. Point-of-Care Glucose Testing Market Size, 2024 to 2033

Key Takeaways:

  • Accu-Chek Inform II accounted for the largest market share of 18.9% in 2023.
  • Freestyle lite is expected to witness the fastest growth over the forecast period.

U.S. Point-of-Care Glucose Testing Market Growth

The increasing increase in the senior population, better accuracy of point-of-care devices, and quick improvements in mobile glucose monitoring apps are all driving market expansion.

In 2023, the United States accounted for more than 34% of the global point-of-care glucose testing market. The large population at high risk of diabetes in the United States contributes significantly to product demand growth. According to the Centers for Disease Control and Prevention, diabetes is the seventh leading cause of mortality in the United States, with approximately 38.4 million (11.6% of the population) Americans diagnosed in 2021. The presence of government groups dedicated to raising awareness about diabetes and glucose testing items on the market has fueled the country's growth. For example, the American Heart Association, the American Diabetes Association, and the Pan American Health Organization are all heavily active in such projects.

Rising healthcare expenditure for diabetes, as well as rising diabetes-related costs per person, are driving demand. Manufacturers in the United States are developing advanced diabetes management platforms, raising demand for point-of-care glucose diagnostic tools. For example, One Drop is a diabetes management startup that combines data science and mobile computing.

U.S. Point-of-Care Glucose Testing Market Report Scope

Report Attribute Details
Market Size in 2024 USD 1.27 Billion
Market Size by 2033 USD 1.90 Billion
Growth Rate From 2024 to 2033 CAGR of 4.6%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered Product
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Key Companies Profiled F. Hoffmann-La Roche Ltd.; Abbott; Nipro; Platinum Equity Advisors, LLC (Lifescan, Inc.); Nova Biomedical; ACON Laboratories; Trividia Health, Inc.; Prodigy Diabetes Care, LLC; Bayer AG/Ascensia Diabetes Care Holdings AG; EKF Diagnostics

 

U.S. Point-of-Care Glucose Testing Market Trends

  • Technological Advancements: Continuous innovation in glucose monitoring technologies, including the development of minimally invasive or non-invasive devices, has been a significant trend. These advancements aim to enhance user experience, accuracy, and convenience.
  • Integration with Digital Health Platforms: There's a growing trend toward integrating POC glucose testing devices with digital health platforms and mobile applications. This integration allows for real-time monitoring, data sharing with healthcare providers, and better management of diabetes.
  • Rising Incidence of Diabetes: The increasing prevalence of diabetes in the United States continues to drive the demand for POC glucose testing devices. As more individuals require regular monitoring of their blood glucose levels, the market for these devices expands.
  • Demand for Portable and Convenient Solutions: Consumers are increasingly seeking portable and user-friendly POC glucose testing devices that allow for testing anytime, anywhere. This demand drives manufacturers to develop compact, easy-to-use devices suitable for home and on-the-go use.
  • Shift Towards Non-Invasive Monitoring: While traditional fingerstick methods remain prevalent, there's a growing interest in non-invasive or minimally invasive glucose monitoring technologies. These methods offer greater comfort and convenience for users, potentially leading to increased adoption rates.
  • Focus on Accuracy and Precision: Accuracy and precision remain paramount in glucose monitoring devices, especially for clinical decision-making. Manufacturers are continually refining their technologies to ensure reliable and consistent glucose readings.
  • Market Consolidation and Partnerships: The POC glucose testing market has seen some consolidation as larger healthcare companies acquire smaller device manufacturers or form strategic partnerships to broaden their product portfolios and reach a wider customer base.
  • Regulatory Landscape: Regulatory requirements and compliance standards continue to evolve, influencing product development and market entry strategies. Companies must navigate these regulations to ensure their devices meet safety and performance standards.

U.S. Point-of-Care Glucose Testing Market By Product Insights

Accu-Chek Inform II held the greatest market share of 18.9% in 2023. This product is intended for in-vitro diagnostic methods that assist monitor blood glucose levels. This glucose meter measures the concentration of blood glucose in venous, capillary, whole blood, neonatal, and arterial samples. Several healthcare professionals utilize Accu-Check Inform II as a bedside monitoring tool that aids in glucose assessment and automates data management from blood glucose testing. This enables healthcare providers to provide superior patient care.

Freestyle light is predicted to expand the fastest during the projection period. Abbott's FreeStyle Lite comes in a compact size with an inbuilt backlight and port light, making it ideal for patients who lead a busy lifestyle. This gadget is used to measure blood glucose levels from blood samples taken from the fingers, upper arm, forearm, hand, and thighs.

U.S. Point-of-Care Glucose Testing Market Recent Developments

  • In January 2024, Roche announced the acquisition of LumiraDx’s point of care technology in a deal valuing over USD 350 million. This deal offered Roche a diverse range of clinical chemistry and immunoassay tests, having the potential for added high-medical value tests in the upcoming years.
  • In February 2023, Insulet Corporation acquired the assets of Automated Glucose Control LLC (AGC). AGC specializes in automated insulin delivery technology. With the help of this transaction, Insulet planned to make prominent innovations in developing automated insulin delivery technology.

Key U.S. Point-of-Care Glucose Testing Company Insights

Some of the key U.S. point-of-care glucose testing players in are F. Hoffmann-La Roche Ltd., Abbott, LifeScan, Inc., and Bayer AG/Ascensia Diabetes Care Holdings AG among others. The industry is highly fragmented with the presence of many large, small, and medium-scale manufacturers. Key players are focusing on various business growth strategies, including new product launches, collaborations, expansion, partnerships, and acquisitions.

U.S. Point-of-Care Glucose Testing Market Top Key Companies:

  • F. Hoffmann-La Roche Ltd.
  • Abbott
  • Nipro
  • Platinum Equity Advisors, LLC (Lifescan, Inc.)
  • Nova Biomedical
  • ACON Laboratories
  • Trividia Health, Inc.
  • Prodigy Diabetes Care, LLC
  • Bayer AG/Ascensia Diabetes Care Holdings AG
  • EKF Diagnostics

U.S. Point-of-Care Glucose Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Point-of-Care Glucose Testing market.

By Product 

  • Accu Check Aviva Meter
  • Onetouch Verio Flex
  • i-STAT
  • Freestyle Lite
  • Bayer CONTOUR Blood Glucose Monitoring System
  • True Metrix
  • Accu-Chek Inform II
  • StatStrip
  • Others

Frequently Asked Questions

The U.S. point-of-care glucose testing market size was estimated at USD 1.21 billion in 2023 and is projected to hit around USD 1.90 billion by 2033

Key factors that are driving the market growth include growing geriatric population, the ability of point-of-care (POC) diagnostic tests to deliver immediate results, thus providing improved patient care, and rising market penetration of electronic medical records (EMRs) are among the high-impact rendering drivers of this market.

Some key players operating in the U.S. point-of-care glucose testing market include F. Hoffmann-La Roche Ltd.; Abbott; Nipro; PlatInium Equity Advisors, LLC (Lifescan, Inc.); Nova Biomedical; ACON Laboratories; Trividia Health, Inc.; Prodigy Diabetes Care, LLC; Bayer AG/Ascensia Diabetes Care Holdings AG; EKF Diagnostics.

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                        1.1.1. Product
                        1.1.2. Estimates and forecast timeline
                    1.2. Research Methodology
                    1.3. Information Procurement
                        1.3.1. Purchased database
                        1.3.2. nova one advisor’s internal database
                        1.3.3. Secondary sources
                        1.3.4. Primary research
                    1.4. Information or Data Analysis
                        1.4.1. Data analysis models
                    1.5. Market Formulation & Validation
                    1.6. Model Details
                        1.6.1. Commodity flow analysis (Model 1)
                            1.6.1.1. Approach 1: Commodity flow approach
                        1.6.2. Volume price analysis (Model 2)
                            1.6.2.1. Approach 2: Volume price analysis
                    1.7. List of Secondary Sources
                    1.8. List of Primary Sources
                    1.9. Objectives
                        1.9.1. Objective - 1
                        1.9.2. Objective - 2
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                        2.2.1. Product outlook
                    2.3. Competitive Insights
Chapter 3. Point-of-Care (POC) Glucose Testing Market Variables, Trends & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent market outlook
                        3.1.2. Related/ancillary market outlook
                    3.2. Penetration & Growth Prospect Mapping
                    3.3. Industry Value Chain Analysis
                        3.3.1. Reimbursement framework
                    3.4. Market Dynamics
                        3.4.1. Market driver analysis
                            3.4.1.1. Introduction of CLIA waived tests
                            3.4.1.2. Growing prevalence of diabetes
                            3.4.1.3. Rising demand for short turnaround time glucose POC testing
                        3.4.2. Market restraint analysis
                            3.4.2.1. Potential interference and calibration issues in glucose meters
                            3.4.2.2. Presence of ambiguous regulatory as well as reimbursement framework
                    3.5. Point-of-Care(POC) Glucose Testing Market Analysis Tools
                        3.5.1. Industry Analysis - Porter’s Five Forces
                            3.5.1.1. Supplier power
                            3.5.1.2. Buyer power
                            3.5.1.3. Substitution threat
                            3.5.1.4. Threat of new entrant
                            3.5.1.5. Competitive rivalry
                        3.5.2. PESTEL Analysis
                            3.5.2.1. Political landscape
                            3.5.2.2. Technological landscape
                            3.5.2.3. Economic landscape
                        3.5.3. Major Deals & Strategic Alliances Analysis
                        3.5.4. Market Entry Strategies
Chapter 4. U.S. Point-of-Care (POC) Glucose Testing Market: Product Estimates & Trend Analysis
                    4.1. Definitions and Scope
                    4.2. Product Market Share, 2018 & 2030
                    4.3. Segment Dashboard
                    4.4. U.S. Point-of-Care (POC) Glucose Testing Market by Product Outlook
                    4.5. Market Size & Forecasts and Trend Analyses, 2021 – 2033 for the following
                        4.5.1. Accu-Check Aviva Meter
                            4.5.1.1. Accu-Check Aviva Meter market estimates and forecast, 2021 - 2033
                        4.5.2. Onetouch Verio Flex
                            4.5.2.1. Onetouch Verio Flex market estimates and forecast, 2021 - 2033
                        4.5.3. i-STAT
                            4.5.3.1. I-STAT market estimates and forecast, 2021 - 2033
                        4.5.4. Freestyle Lite
                            4.5.4.1. Freestyle Lite market estimates and forecast, 2021 - 2033
                        4.5.5. Bayer Contour Blood Glucose Monitoring System
                            4.5.5.1. Bayer Contour Blood Glucose Monitoring System market estimates and forecast, 2021 - 2033
                        4.5.6. True Metrix
                            4.5.6.1. TRUE METRIX market estimates and forecast, 2021 - 2033
                        4.5.7. Accu-Check Inform II
                            4.5.7.1. Accu-Check Inform II market estimates and forecast, 2021 - 2033
                        4.5.8. StatStrip
                            4.5.8.1. StatStrip market estimates and forecast, 2021 - 2033
                        4.5.9. Others
                            4.5.9.1. Others market estimates and forecast, 2021 - 2033
Chapter 5. Competitive Landscape
                    5.1. Recent Developments & Impact Analysis, By Key Market Participants
                    5.2. Company/Competition Categorization
                        5.2.1. Innovators
                    5.3. Vendor Landscape
                        5.3.1. List of key distributors and channel partners
                        5.3.2. Key customers
                        5.3.3. Key company market share analysis, 2021
                        5.3.4. F. Hoffmann-La Roche Ltd.
                            5.3.4.1. Company overview
                            5.3.4.2. Financial performance
                            5.3.4.3. Product benchmarking
                            5.3.4.4. Strategic initiatives
                        5.3.5. Abbott
                            5.3.5.1. Company overview
                            5.3.5.2. Financial performance
                            5.3.5.3. Product benchmarking
                            5.3.5.4. Strategic initiatives
                        5.3.6. Nipro
                            5.3.6.1. Company overview
                            5.3.6.2. Financial performance
                            5.3.6.3. Product benchmarking
                            5.3.6.4. Strategic initiatives
                        5.3.7. Platinum Equity Advisors, LLC (Lifescan, Inc.)
                            5.3.7.1. Company overview
                            5.3.7.2. Financial performance
                            5.3.7.3. Product benchmarking
                            5.3.7.4. Strategic initiatives
                        5.3.8. Nova Biomedical
                            5.3.8.1. Company overview
                            5.3.8.2. Financial performance
                            5.3.8.3. Product benchmarking
                            5.3.8.4. Strategic initiatives
                        5.3.9. ACON Laboratories
                            5.3.9.1. Company overview
                            5.3.9.2. Financial performance
                            5.3.9.3. Product benchmarking
                            5.3.9.4. Strategic initiatives
                        5.3.10. Trividia Health, Inc.
                            5.3.10.1. Company overview
                            5.3.10.2. Financial performance
                            5.3.10.3. Product benchmarking
                            5.3.10.4. Strategic initiatives
                        5.3.11. Prodigy Diabetes Care, LLC
                            5.3.11.1. Company overview
                            5.3.11.2. Financial performance
                            5.3.11.3. Product benchmarking
                            5.3.11.4. Strategic initiatives
                        5.3.12. Bayer AG/Ascensia Diabetes Care Holdings AG
                            5.3.12.1. Company overview
                            5.3.12.2. Financial performance
                            5.3.12.3. Product benchmarking
                            5.3.12.4. Strategic initiatives
                        5.3.13. EKF Diagnostics
                            5.3.13.1. Company overview
                            5.3.13.2. Financial performance
                            5.3.13.3. Product benchmarking
                            5.3.13.4. Strategic initiatives

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask To Expert